Sign inJoin waitlistJoin the waitlist

AH

Ahmad Hanif

Physician · Geisinger

Credentials: · · · · · · ·

History

Geisinger
2022–Present

Hematology and Medical Oncology
Medical College of Wisconsin Affiliated Hospitals, Inc
2014–2017
Internal Medicine
2011–2014
School
2004–2008

Research

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors
Biology of Blood and Marrow Transplantation · 2016 · 112 citations
Thrombotic complications and anticoagulation in COVID-19 pneumonia: a New York City hospital experience
Annals of Hematology · 2020 · First of 12 authors · Corresponding · 46 citations
Current and Emerging Treatment Options for Pancreatic Cancer: A Comprehensive Review
Review · Journal of Clinical Medicine · 2025 · Last of 9 authors · 35 citations

DZ
Darryl Zeldin
5 papers
SK
Sumera Khan
3 papers · 2 as a resident
Kevin Jain
2 papers
Laura Michaelis
2 papers
MA
Muhammad Adrish
2 papers
AC
Ankush Chander
1 paper
Asel Saadeh
1 paper · 1 as a resident
Ashleigh Barrickman
1 paper
AH
Asim Haider
1 paper · 1 as a resident
Ayesha Siddiqa
1 paper · 1 as a fellow
Bharat Bajantri
1 paper · 1 as a fellow
Brenda Ernst
1 paper · 1 as a fellow

Clinical trials

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2023–2028
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Site PI · Recruiting
SWOG Cancer Research Network
2021–2028
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2020–2027
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Site PI · Recruiting · Phase 3
SWOG Cancer Research Network
2018–2031